How a Healthy Gut Could Lead to Better Bone Marrow Transplants

In a new study, researchers looked for alterations in the gut microbiome to see whether its metabolites could improve outcomes after bone marrow transplants.

1:00 PM

Author | Nicole Fawcett

Could playing better defense make bone marrow transplants more successful?

With this question in mind, researchers began looking at whether the trillions of little bugs and bacteria living in our gastrointestinal tract could be the key to playing defense.

Up to half of patients who receive a bone marrow transplant from a donor will develop severe gastrointestinal damage from graft-versus-host disease, a condition in which the donor cells attack the host's body. It's the reason why transplants — which can be very successful at eliminating cancers such as leukemia or lymphoma — are so risky.

In a new study, published in Nature Immunology, researchers looked for alterations in the gut microbiome to see whether its metabolites could improve outcomes after bone marrow transplant.

They found that a metabolite called butyrate was significantly reduced in the intestinal tract of experimental mice that received bone marrow transplant. When the researchers increased butyrate in these mouse models, they saw a decrease in the incidence and severity of graft-versus-host disease.

"Our findings suggest we can prevent graft-versus-host disease by bolstering the amount of the microbiome-derived metabolite butyrate," says study lead author Pavan Reddy, M.D., the Moshe Talpaz Professor of Translational Pathology and interim division chief of hematology/oncology at the University of Michigan.

This is a whole new approach. The idea is to make the host cells stronger, to be able to withstand the assault of the donor immune cells while reducing the risk of infection or leukemia relapse.
Pavan Reddy, M.D.

"If the GI gut lining can remain healthy and strong, it can resist the attack by the donor immune system and hopefully prevent graft-versus-host disease," he adds.

The researchers found that shifts in the gut's microbes result in a decrease in butyrate. When they manipulated the microbes back to their original form, the butyrate would come back up and mitigate graft-versus-host disease.

Diet is one way to control butyrate production by the gut microbiome, specifically through resistant starch such as that found in potatoes. Researchers hope to begin a clinical trial later this year that will look at combining resistant starch with current methods of preventing graft-versus-host to assess whether they can increase butyrate — and reduce graft-versus-host.

Current methods of preventing graft-versus-host involve suppressing the immune system, which suppresses the ability of the donor immune system to cause graft-versus-host disease. But it also means that other normal immune system functions are suppressed. Those functions include fighting infections or preventing cancer from returning.

"This is a whole new approach. The idea is to make the host cells stronger, to be able to withstand the assault of the donor immune cells while reducing the risk of infection or leukemia relapse," Reddy says.

This study was funded by National Institutes of Health grants HL-090775, HL-128046, CA-173878.


More Articles About:

Lab Report Bone and Marrow Transplant (BMT) Leukemia Cancer: Help, Diagnosis & Treatment Bone Marrow Transplant (BMT)
Health Lab word mark overlaying blue cells

Health Lab

Explore a variety of health care news & stories by visiting the Health Lab home page for more articles.

Media Contact

University Hospital at U-M Health in the spring with flowering trees in foreground and Survival Flight helicopter visible

Public Relations

Department of Communication at Michigan Medicine

[email protected]

734-764-2220

Stay Informed

Want top health & research news weekly? Sign up for Health Lab’s newsletters today!

Subscribe

Featured News & Stories

The Fundamentals Podcast Hero Card Final 1800 x 1350
The Fundamentals

The Future of Cell and Gene Therapies

On this episode of The Fundamentals, we talked to physician scientist, Dr. Monalisa Ghosh, assistant professor of medical oncology and internal medicine, who is looking to expand CAR-T's application from cancer to autoimmune disorders and beyond.
yellow black purple red cell in middle mostly black
Health Lab

Study sheds light on how early pancreas lesions become cancerous

Why many precursor lesions never develop into pancreatic cancer, according to findings from Michigan Medicine.
Well-Being at Michigan Medicine with Dr. Elizabeth Harry
Well-Being at Michigan Medicine

Honoring the Heart of Care: Nurse Well-Being in Action

In this special Nurses Week episode, Chief Well-Being Officer Elizabeth Harry, M.D., chats with nurse leaders Denise Ervin, D.N.P., R.N., NC-BC, and Tonie Owens, M.S.N., R.N., about resilience, teamwork and the evolving future of nursing. They share personal stories, “sacred moments” in care and practical ways teams support well-being on the front lines. The conversation highlights both the challenges nurses face and the culture of connection that helps them thrive.
Cancer Aware surrounded by a circle of multicolor ribbons
Cancer Aware

CAR T-cell Therapy

Using one's cells to attack and treat cancer continues to grow. Cellular therapy and in particular CAR T-cell therapy offers new opportunities to adult and pediatric patients with blood cancers like leukemia and lymphoma. Dr. Monalisa Ghosh, Rogel Cancer Center oncologist talks about these treatments and and the future of cellular therapy.
sisters together 15 years ago on left and on right today
Health Lab

Sisters celebrate a successful bone marrow donation 15 years later

Two sisters are celebrating 15 years of life after a bone marrow transplant. The transplant treated symptoms of Stage IV non-Hodgkin’s lymphoma and has allowed the sisters to share time together they were not sure they were going to have.
The Rogel Cancer Center building
News Release

U-M researcher receives Cancer Grand Challenges funding to crack the dark proteome of cancer

John Prensner, MD, PhD at University of Michigan Health C.S. Mott Children’s Hospital and research member at the Rogel Cancer Center is part of a research team called ILLUMINE which will receive a Cancer Grand Challenges award.